vs
Adaptive Biotechnologies Corp（ADPT）与AIM ImmunoTech Inc.（AIM）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是AIM ImmunoTech Inc.的3413.4倍（$71.7M vs $21.0K）。Adaptive Biotechnologies Corp净利率更高（-18.9% vs -19881.0%，领先19862.0%）。Adaptive Biotechnologies Corp同比增速更快（51.0% vs -53.3%）。过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs -27.5%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
ADPT vs AIM — 直观对比
营收规模更大
ADPT
是对方的3413.4倍
$21.0K
营收增速更快
ADPT
高出104.4%
-53.3%
净利率更高
ADPT
高出19862.0%
-19881.0%
两年增速更快
ADPT
近两年复合增速
-27.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $21.0K |
| 净利润 | $-13.6M | $-4.2M |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | -14057.1% |
| 净利率 | -18.9% | -19881.0% |
| 营收同比 | 51.0% | -53.3% |
| 净利润同比 | 59.7% | 30.0% |
| 每股收益（稀释后） | $-0.08 | $-6.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTAIM
| Q4 25 | $71.7M | $21.0K | ||
| Q3 25 | $94.0M | $26.0K | ||
| Q2 25 | $58.9M | $25.0K | ||
| Q1 25 | $52.4M | $16.0K | ||
| Q4 24 | $47.5M | $45.0K | ||
| Q3 24 | $46.4M | $35.0K | ||
| Q2 24 | $43.2M | $50.0K | ||
| Q1 24 | $41.9M | $40.0K |
净利润ADPTAIM
| Q4 25 | $-13.6M | $-4.2M | ||
| Q3 25 | $9.5M | $-3.3M | ||
| Q2 25 | $-25.6M | $-2.8M | ||
| Q1 25 | $-29.9M | $-3.7M | ||
| Q4 24 | $-33.7M | $-6.0M | ||
| Q3 24 | $-32.1M | $-3.7M | ||
| Q2 24 | $-46.2M | $-1.8M | ||
| Q1 24 | $-47.5M | $-5.8M |
毛利率ADPTAIM
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTAIM
| Q4 25 | -17.8% | -14057.1% | ||
| Q3 25 | 10.9% | -9411.5% | ||
| Q2 25 | -42.5% | -10584.0% | ||
| Q1 25 | -56.4% | -22618.8% | ||
| Q4 24 | -71.3% | -13011.1% | ||
| Q3 24 | -70.3% | -12825.7% | ||
| Q2 24 | -109.6% | -7388.0% | ||
| Q1 24 | -116.5% | -14335.0% |
净利率ADPTAIM
| Q4 25 | -18.9% | -19881.0% | ||
| Q3 25 | 10.2% | -12630.8% | ||
| Q2 25 | -43.5% | -11176.0% | ||
| Q1 25 | -56.9% | -23156.3% | ||
| Q4 24 | -71.0% | -13260.0% | ||
| Q3 24 | -69.1% | -10571.4% | ||
| Q2 24 | -107.0% | -3672.0% | ||
| Q1 24 | -113.5% | -14542.5% |
每股收益（稀释后）ADPTAIM
| Q4 25 | $-0.08 | $-6.46 | ||
| Q3 25 | $0.06 | $1.57 | ||
| Q2 25 | $-0.17 | $-3.68 | ||
| Q1 25 | $-0.20 | $-0.05 | ||
| Q4 24 | $-0.22 | $-21.80 | ||
| Q3 24 | $-0.22 | $-6.00 | ||
| Q2 24 | $-0.31 | $-3.00 | ||
| Q1 24 | $-0.33 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $3.0M |
| 总债务越低越好 | — | $4.5M |
| 股东权益账面价值 | $218.8M | $-9.8M |
| 总资产 | $512.7M | $5.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTAIM
| Q4 25 | $70.5M | $3.0M | ||
| Q3 25 | $55.0M | $2.4M | ||
| Q2 25 | $43.2M | $835.0K | ||
| Q1 25 | $50.6M | $2.2M | ||
| Q4 24 | $47.9M | $4.0M | ||
| Q3 24 | $38.1M | $7.2M | ||
| Q2 24 | $59.8M | $10.1M | ||
| Q1 24 | $71.2M | $10.9M |
总债务ADPTAIM
| Q4 25 | — | $4.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $3.3M | ||
| Q2 24 | — | $3.3M | ||
| Q1 24 | — | $3.3M |
股东权益ADPTAIM
| Q4 25 | $218.8M | $-9.8M | ||
| Q3 25 | $204.4M | $-6.1M | ||
| Q2 25 | $179.7M | $-6.5M | ||
| Q1 25 | $190.4M | $-3.9M | ||
| Q4 24 | $202.7M | $-1.3M | ||
| Q3 24 | $223.8M | $2.9M | ||
| Q2 24 | $241.6M | $6.1M | ||
| Q1 24 | $274.9M | $4.8M |
总资产ADPTAIM
| Q4 25 | $512.7M | $5.8M | ||
| Q3 25 | $490.6M | $5.5M | ||
| Q2 25 | $496.6M | $4.1M | ||
| Q1 25 | $510.9M | $6.2M | ||
| Q4 24 | $539.4M | $8.6M | ||
| Q3 24 | $558.5M | $13.6M | ||
| Q2 24 | $584.9M | $15.7M | ||
| Q1 24 | $620.3M | $16.2M |
负债/权益比ADPTAIM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $-2.0M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | — |
| 自由现金流率自由现金流/营收 | 2.0% | — |
| 资本支出强度资本支出/营收 | 0.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-48.9M | — |
8季度趋势，按日历期对齐
经营现金流ADPTAIM
| Q4 25 | $2.1M | $-2.0M | ||
| Q3 25 | $-7.1M | $-5.1M | ||
| Q2 25 | $-12.4M | $-1.5M | ||
| Q1 25 | $-28.5M | $-2.4M | ||
| Q4 24 | $-12.5M | $-4.0M | ||
| Q3 24 | $-27.1M | $-3.1M | ||
| Q2 24 | $-17.3M | $-3.0M | ||
| Q1 24 | $-38.4M | $-4.8M |
自由现金流ADPTAIM
| Q4 25 | $1.4M | — | ||
| Q3 25 | $-7.5M | — | ||
| Q2 25 | $-13.1M | — | ||
| Q1 25 | $-29.7M | — | ||
| Q4 24 | $-12.6M | — | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-39.9M | — |
自由现金流率ADPTAIM
| Q4 25 | 2.0% | — | ||
| Q3 25 | -8.0% | — | ||
| Q2 25 | -22.2% | — | ||
| Q1 25 | -56.7% | — | ||
| Q4 24 | -26.5% | — | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | — | ||
| Q1 24 | -95.2% | — |
资本支出强度ADPTAIM
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 3.6% | — |
现金转化率ADPTAIM
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
AIM
暂无分部数据
